Cancer Biology & Genetics Program
The Viviane Tabar Lab
I am a neurosurgeon-scientist and Chair of the Department of Neurosurgery. I have clinical expertise in the surgical management of brain tumors such as complex gliomas, meningiomas and skull base tumors. My lab focus is the study of human stem cells for regenerative purposes in the brain, but also as tools for the study of brain tumors.
Piao, Major, Auyeung, Policarpio, Menon, Droms, Gutin, Uryu, Tchieu, Soulet and Tabar. Human embryonic stem cell-derived oligodendrocyte progenitors remyelinate the brain and rescue behavioral deficits following radiation. Cell Stem Cell. 2015 Feb 5;16(2):198-210.
Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science. 2014 Dec 19;346(6216):1529-33.
Tabar V, Studer L. Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat Rev Genet. 2014 Feb;15(2):82-92.
Hicks M.J. et al. Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Ther. 2015 Jan; 22(1);1-8.
Tabar V. Making a pituitary gland in a dish. Call Stem Cell. 2011. Dec 2;9(6):490-1.
Viviane Tabar, MD
- Physician-scientist Viviane Tabar focuses on stem cells as tools for brain repair and for modeling brain cancer.
- MD, American University of Beirut
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Viviane Tabar discloses the following relationships and financial interests:
Intellectual Property Rights; Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.